Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies
- Status
- CompletedResults none
- Why it is watched
- non-weight indication: cerebrovascular
- Who it enrolls
- age 18 Years to 100 Years; no BMI minimum stated; conditions: Stroke; Stroke, Acute; Stroke, Ischemic; Brain Diseases
- Interventions
- Semaglutide
- Conditions
- Stroke; Stroke, Acute; Stroke, Ischemic; Brain Diseases
- Phase and size
- Phase 2 · 140 participants
- Dates
- Start 2023-08-01
Primary completion 2024-10-25 - Sponsor
- Chinese University of Hong Kong (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Change of Modified Rankin ScoreDay 90
- Composite Safety OutcomeDay 90
02Eligibility
Who can take part
Inclusion Criteria: * LVO stroke at terminal ICA or proximal M1 eligible for emergency endovascular treatment as per current treatment guideline. * LKW-to-puncture time ≤ 12 hours. * Age 18 years or greater. * National Institute of Health Stroke Scale (NIHSS) ≥10 * LVO stroke due to thromboembolism or intracranial stenosis (acute or acute on chronic occlusion). * Patients who received computer tomographic angiography and perfusion (CTA+P). * Pre-stroke (24 hours prior to stroke onset) independent functional status with modified Rankin Scale (mRS) ≤ 2. * Consent process completed as per national laws and regulation and the applicable ethics committee requirements. Exclusion Criteria: * ASPECT score ≤ 5. * Intracranial hemorrhage on pre-EVT imaging. * LVO etiologies other than thromboembolism or intracranial stenosis (acute or acute on chronic total occlusion), e.g. arterial dissection, infective endocarditis on initial diagnostic imaging.Estimated or known body mass index \< 18 kg/m2 * Estimated or known body mass index \< 18 kg/m2. * Pregnancy/Lactation; female, with positive urine or serum beta human chorionic gonadotropin (β-hCG) test, or breastfeeding. * Creatinine clearance \< 30mL/min. * Severe or fatal comorbid illness, e.g. terminal malignancy. * Participation in another clinical trial investigating a drug, medical device, or a medical procedure in the 30 days preceding trial inclusion. * History of allergy to GLP-1RA. * Family or personal history of multiple endocrine neoplasia, medullary thyroid carcinoma, pancreatic carcinoma, known proliferative diabetic retinopathy. * Active sepsis on randomization. * Patients with hypoglycaemia on presentation. Defined as capillary or serum glucose level of \<4mmol/L. * Patients prone to severe hypoglycaemia, including chronic kidney disease of estimated glomerular filtration rate of 50ml/min/1.73m\^2; also those with chronic liver disease with Child's Pugh score C or above; patients with recurrent unexplained hypoglycemia. * Patient already on GLP-1RA prior to screening. * Contraindications to iodine-based CT contrast.
03Change log
Registry changes
No changes recorded since the trial was added.